[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT3310331T - Formulações farmacêuticas injetáveis de lefamulina - Google Patents

Formulações farmacêuticas injetáveis de lefamulina

Info

Publication number
PT3310331T
PT3310331T PT167292580T PT16729258T PT3310331T PT 3310331 T PT3310331 T PT 3310331T PT 167292580 T PT167292580 T PT 167292580T PT 16729258 T PT16729258 T PT 16729258T PT 3310331 T PT3310331 T PT 3310331T
Authority
PT
Portugal
Prior art keywords
lefamulin
pharmaceutical formulations
injectable pharmaceutical
injectable
formulations
Prior art date
Application number
PT167292580T
Other languages
English (en)
Original Assignee
Nabriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics GmbH filed Critical Nabriva Therapeutics GmbH
Publication of PT3310331T publication Critical patent/PT3310331T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT167292580T 2015-06-17 2016-06-14 Formulações farmacêuticas injetáveis de lefamulina PT3310331T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562180871P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
PT3310331T true PT3310331T (pt) 2021-01-19

Family

ID=56131530

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167292580T PT3310331T (pt) 2015-06-17 2016-06-14 Formulações farmacêuticas injetáveis de lefamulina

Country Status (27)

Country Link
US (1) US12121582B2 (pt)
EP (1) EP3310331B1 (pt)
JP (1) JP6818019B2 (pt)
KR (1) KR102656841B1 (pt)
CN (1) CN107810000B (pt)
AU (1) AU2016278774C1 (pt)
BR (1) BR112017026904B1 (pt)
CA (1) CA2989372C (pt)
CY (1) CY1123722T1 (pt)
DK (1) DK3310331T3 (pt)
EA (1) EA033988B1 (pt)
ES (1) ES2843723T3 (pt)
HK (1) HK1252534A1 (pt)
HR (1) HRP20210010T1 (pt)
HU (1) HUE053024T2 (pt)
IL (1) IL256115A (pt)
LT (1) LT3310331T (pt)
MX (1) MX2017015812A (pt)
PH (1) PH12017502319A1 (pt)
PL (1) PL3310331T3 (pt)
PT (1) PT3310331T (pt)
RS (1) RS61327B1 (pt)
SI (1) SI3310331T1 (pt)
TW (1) TWI718158B (pt)
UA (1) UA121240C2 (pt)
WO (1) WO2016202788A1 (pt)
ZA (1) ZA201707998B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3180535A1 (en) 2020-04-17 2021-10-21 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
EP4135683A1 (en) * 2020-04-17 2023-02-22 Nabriva Therapeutics GMBH Therapeutic use of pleuromutilins
TW202203907A (zh) 2020-04-17 2022-02-01 奧地利商納畢瓦治療有限責任公司 截短側耳素類的新醫療用途
EP4373960A1 (en) * 2021-07-19 2024-05-29 JBS Science Inc. Methods for isolating circulating nucleic acids from urine samples
WO2023152115A1 (en) 2022-02-09 2023-08-17 Nabriva Therapeutics GmbH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130709A (en) 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
GB2228412B (en) * 1989-02-28 1993-04-14 Syntex Inc Nicardipine pharmaceutical composition for parenteral administration
DE4023848C2 (de) 1990-07-27 1994-04-21 Huels Chemische Werke Ag Verfahren zur Herstellung von 3-C¶1¶- bis C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern
US6187746B1 (en) 1997-12-16 2001-02-13 Rhone-Poulenc Rorer S.A. Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
KR100758441B1 (ko) 2000-04-04 2007-09-14 스미스클라인비이참피이엘시이 항균제용 2―히드록시―무틸린 카르바메이트 유도체
GB0017031D0 (en) 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
CA2593993C (en) * 2004-12-30 2014-07-29 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
TW200730488A (en) * 2005-06-27 2007-08-16 Nabriva Therapeutics Forschungs Gmbh Organic compounds
GB0515995D0 (en) 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2159220A1 (en) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds
US20100331812A1 (en) * 2009-06-29 2010-12-30 Nitric Biotherapeutics, Inc. Pharmaceutical Formulations for Iontophoretic Delivery of an Immunomodulator
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103626693B (zh) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
EP3003307B1 (en) * 2013-05-28 2020-11-11 Morphochem GmbH Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
TWI762573B (zh) * 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化

Also Published As

Publication number Publication date
KR102656841B1 (ko) 2024-04-12
CN107810000B (zh) 2021-03-12
EP3310331A1 (en) 2018-04-25
RS61327B1 (sr) 2021-02-26
ES2843723T3 (es) 2021-07-20
CA2989372A1 (en) 2016-12-22
US20180360966A1 (en) 2018-12-20
JP6818019B2 (ja) 2021-01-20
SI3310331T1 (sl) 2021-02-26
KR20180030479A (ko) 2018-03-23
UA121240C2 (uk) 2020-04-27
HK1252534A1 (zh) 2019-05-31
AU2016278774C1 (en) 2021-11-18
JP2018517777A (ja) 2018-07-05
CA2989372C (en) 2023-10-03
BR112017026904B1 (pt) 2023-10-10
WO2016202788A1 (en) 2016-12-22
EA033988B1 (ru) 2019-12-17
MX2017015812A (es) 2018-07-06
PH12017502319A1 (en) 2018-06-25
TW201716056A (zh) 2017-05-16
PL3310331T3 (pl) 2021-04-19
CN107810000A (zh) 2018-03-16
CY1123722T1 (el) 2022-05-27
ZA201707998B (en) 2021-04-28
BR112017026904A2 (pt) 2018-08-14
AU2016278774B2 (en) 2021-07-29
EA201890075A1 (ru) 2018-05-31
TWI718158B (zh) 2021-02-11
AU2016278774A1 (en) 2017-12-07
EP3310331B1 (en) 2020-10-14
IL256115A (en) 2018-02-28
LT3310331T (lt) 2021-01-11
HUE053024T2 (hu) 2021-06-28
US12121582B2 (en) 2024-10-22
HRP20210010T1 (hr) 2021-03-05
DK3310331T3 (da) 2021-01-11

Similar Documents

Publication Publication Date Title
HK1243650A1 (zh) 包含美洛昔康的藥物組合物
IL287947A (en) Viscosity reduction of pharmaceutical preparations
SI4070788T1 (sl) Farmacevtske formulacije
HK1254343A1 (zh) 藥物製劑
HK1252534A1 (zh) 來氟米林的可注射藥物組合物
ZA201707094B (en) Pharmaceutical formulations
IL267279A (en) Pharmaceutical formulations of suvorexant
HK1245073A1 (zh) 藥物組合物
ZA201705329B (en) Pharmaceutical formulations of racecadotril
IL252729A0 (en) Injectable formulations of acetaminophen
PL3319596T3 (pl) Farmaceutyczne kompozycje
GB201506598D0 (en) Pharmaceutical compositions